CN1882546A - 用于治疗神经病疼痛的吡啶－4－基胺化合物 - Google Patents

用于治疗神经病疼痛的吡啶－4－基胺化合物 Download PDF

Info

Publication number
CN1882546A
CN1882546A CNA2004800341960A CN200480034196A CN1882546A CN 1882546 A CN1882546 A CN 1882546A CN A2004800341960 A CNA2004800341960 A CN A2004800341960A CN 200480034196 A CN200480034196 A CN 200480034196A CN 1882546 A CN1882546 A CN 1882546A
Authority
CN
China
Prior art keywords
alkyl
compound
halogen
hydrogen
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800341960A
Other languages
English (en)
Chinese (zh)
Inventor
J·林
J·K·布埃尔斯
B·穆诺兹
R·普拉茨托
N·斯托克
S·文卡特拉曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of CN1882546A publication Critical patent/CN1882546A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C07D219/12—Amino-alkylamino radicals attached in position 9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2004800341960A 2003-11-21 2004-11-18 用于治疗神经病疼痛的吡啶－4－基胺化合物 Pending CN1882546A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52473403P 2003-11-21 2003-11-21
US60/524,734 2003-11-21

Publications (1)

Publication Number Publication Date
CN1882546A true CN1882546A (zh) 2006-12-20

Family

ID=34632928

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800341960A Pending CN1882546A (zh) 2003-11-21 2004-11-18 用于治疗神经病疼痛的吡啶－4－基胺化合物

Country Status (7)

Country Link
US (1) US20070099950A1 (https=)
EP (1) EP1687275A4 (https=)
JP (1) JP2007512341A (https=)
CN (1) CN1882546A (https=)
AU (1) AU2004292546A1 (https=)
CA (1) CA2545786A1 (https=)
WO (1) WO2005051915A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107721925A (zh) * 2017-09-12 2018-02-23 上海交通大学 一种新型乙酰胆碱酯酶抑制剂及其制备方法和应用
CN111050800A (zh) * 2017-06-28 2020-04-21 国立大学法人大阪大学 血清素3受体激动剂对疼痛的治疗
CN112300071A (zh) * 2020-11-25 2021-02-02 张家港威胜生物医药有限公司 一种高纯度磷酸氯喹的合成方法
CN114149410A (zh) * 2020-09-07 2022-03-08 四川科伦博泰生物医药股份有限公司 吡啶并环类化合物及其制备方法和用途

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083388A2 (en) 2003-03-14 2004-09-30 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
WO2006127329A1 (en) 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Quinoline derivatives useful as modulators of ion channels
HRP20201384T1 (hr) 2014-01-01 2020-11-27 Medivation Technologies Llc Spojevi i postupci njihove upotrebe
GB2568291A (en) * 2017-11-13 2019-05-15 Crisby Milita New use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2077249A (en) * 1934-06-06 1937-04-13 Winthrop Chem Co Inc Basically substituted acridine compounds
US3066141A (en) * 1957-04-26 1962-11-27 Jr Ralph Jones Quinoline-type mustards and process for producing same
US5021426A (en) * 1990-02-26 1991-06-04 Merck & Co., Inc. Method of traeting malaria with cyproheptadine derivatives
EP0446604A3 (en) * 1990-03-16 1992-02-19 American Cyanamid Company Pyridine and related aza heterocycle derivatives as cardiovascular agents
FR2676228B1 (fr) * 1991-05-07 1995-01-06 Rhone Poulenc Chimie Procede de preparation de sulfate de chloroquine.
WO1996039818A1 (en) * 1995-06-07 1996-12-19 Cerus Corporation Treating red blood cell solutions with anti-viral agents
US5783584A (en) * 1995-12-11 1998-07-21 Mayo Foundation For Medical Education And Research THA analogs useful as cholinesterase inhibitors
AU1290700A (en) * 1998-12-02 2000-06-19 Pfizer Products Inc. Methods and compositions for restoring conformational stability of a protein of the p53 family
US6194403B1 (en) * 1999-09-09 2001-02-27 Unitech Pharmaceuticals, Inc. Tacrine derivatives for treating Alzheimer's disease

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111050800A (zh) * 2017-06-28 2020-04-21 国立大学法人大阪大学 血清素3受体激动剂对疼痛的治疗
CN107721925A (zh) * 2017-09-12 2018-02-23 上海交通大学 一种新型乙酰胆碱酯酶抑制剂及其制备方法和应用
CN107721925B (zh) * 2017-09-12 2020-02-14 上海交通大学 一种新型乙酰胆碱酯酶抑制剂及其制备方法和应用
CN114149410A (zh) * 2020-09-07 2022-03-08 四川科伦博泰生物医药股份有限公司 吡啶并环类化合物及其制备方法和用途
CN112300071A (zh) * 2020-11-25 2021-02-02 张家港威胜生物医药有限公司 一种高纯度磷酸氯喹的合成方法

Also Published As

Publication number Publication date
JP2007512341A (ja) 2007-05-17
CA2545786A1 (en) 2005-06-09
AU2004292546A1 (en) 2005-06-09
EP1687275A4 (en) 2009-01-14
US20070099950A1 (en) 2007-05-03
WO2005051915A1 (en) 2005-06-09
EP1687275A1 (en) 2006-08-09

Similar Documents

Publication Publication Date Title
CN1247588C (zh) 腺苷A2a受体拮抗剂
CN1289499C (zh) 吡嗪并(氮杂)吲哚衍生物
CN1115336C (zh) 1－苯基－苯并咪唑类化合物及其作为baga－a受体调节剂的用途
CN1165537C (zh) 作为5-ht2c兴奋剂的吡咯并吲哚、吡啶并吲哚和氮杂�并吲哚
CN1072219C (zh) 二氮杂䓬酮、其生产和用途
CN1671696A (zh) 激酶抑制剂
CN1620455A (zh) 作为5－羟色胺－6配体的氮杂吲哚基烷基胺衍生物
CN100340562C (zh) 杂环稠合的苯并二噁烷的抗抑郁芳基哌嗪衍生物
CN1361779A (zh) 新化合物
CN1278819A (zh) 作为促肾上腺皮质素释放激素拮抗剂、可用于治疗cns障碍和紧张相关性疾病的杂环基取代的环稠合吡啶和嘧啶
CN1150165C (zh) 用于治疗中枢神经系统紊乱的1-芳基磺酰基-2-芳基-吡咯烷衍生物
CN1871008A (zh) 用于治疗神经病变性疼痛的三唑并－哒嗪化合物和它们的衍生物
CN1761646A (zh) 大麻素受体配位体
CN1270585A (zh) 取代的1,2,3,4－四氢化萘衍生物
CN1454211A (zh) 作为Xa因子抑制剂的含氮杂双环化合物
CN1688581A (zh) [1,2,4]－三唑二环腺苷A2ａ受体拮抗剂
CN1788002A (zh) 作为钠通道阻滞剂的联芳基取代的三唑化合物
CN1217711A (zh) 用作选择性多巴胺d3配体的芳基取代的环胺类化合物
CN1732158A (zh) 作为促肾上腺皮质激素释放因子拮抗剂的吲唑衍生物
CN1606553A (zh) 催产素激动药
CN1871242A (zh) 作为mch r1拮抗剂用于治疗肥胖症、糖尿病、抑郁症和焦虑的3－(4－(氨基苯基)噻吩并嘧啶－4－酮衍生物
CN1794990A (zh) 代谢型谷氨酸受体－5的二芳基取代吡咯调节剂
CN1768055A (zh) 作为代谢型谷氨酸受体－5调制剂的四环咪唑衍生物
CN1022322C (zh) 稠合吡唑3-氧代-丙腈衍生物的制备方法
CN1259049A (zh) 可用作5－ht1f激动剂的羧酰胺类

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication